相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-κB activation
Sakiko Ohga et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2007)
Rosiglitazone prevents advanced glycation end products-induced renal toxicity likely through suppression of plasminogen activator inhibitor-1
Xiaoyan Yu et al.
TOXICOLOGICAL SCIENCES (2007)
Rosiglitazone ameliorates diabetic nephropathy by inhibiting reactive oxygen species and its downstream-signaling pathways
Yan Bao et al.
PHARMACOLOGY (2007)
Peroxisome proliferator-activated receptor gamma agonists in renal disease
Pedro Iglesias et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006)
Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats
Sang-Youb Han et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy
R Agarwal
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2006)
Agonist of peroxisome proliferator-activated receptor-γ, rosiglitazone, reduces renal injury and dysfunction in a murine sepsis model
S Lee et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2005)
Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1
LJ Ma et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
An overview on biological mechanisms of PPARs
BP Kota et al.
PHARMACOLOGICAL RESEARCH (2005)
Effect of retinoic acid in experimental diabetic nephropathy
SY Han et al.
IMMUNOLOGY AND CELL BIOLOGY (2004)
Macrophages in mouse type 2 diabetic nephropathy: Correlation with diabetic state and progressive renal injury
F Chow et al.
KIDNEY INTERNATIONAL (2004)
NF-κB activation and overexpression of regulated genes in human diabetic nephropathy
S Mezzano et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2004)
Peroxisome proliferator-activated receptor γ agonist provides superior renal protection versus angiotensin-converting enzyme inhibition in a rat model of type 2 diabetes with obesity
C Baylis et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes
R Utimura et al.
KIDNEY INTERNATIONAL (2003)
Rosiglitazone reduces urinary albumin excretion in type II diabetes
G Bakris et al.
JOURNAL OF HUMAN HYPERTENSION (2003)
Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease
YF Guan et al.
KIDNEY INTERNATIONAL (2001)
Peroxisome proliferator-activated receptor-γ agonist troglitazone protects against nondiabetic glomerulosclerosis in rats
LJ Ma et al.
KIDNEY INTERNATIONAL (2001)
Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in Type 2 diabetic patients with microalbuminuria or macroalbuminuria
T Nakamura et al.
DIABETIC MEDICINE (2001)
Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion
KJ McCarthy et al.
KIDNEY INTERNATIONAL (2000)
Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy
N Banba et al.
KIDNEY INTERNATIONAL (2000)
分享论文
